Hubungan Penaksiran Skor CHA2DS2-VA terhadap Readmisi Pasien Fibrilasi Atrium Non-Valvular
DOI:
https://doi.org/10.35790/r8cccp09Keywords:
skor CHA2DS2-VA; readmisi pasien; fibrilasi atriumAbstract
Abstract: Readmission rates in atrial fibrillation patients remain a high burden on the healthcare system. The CHA2DS2-VA score, an inclusive and practical clinical tool for predicting stroke, also has the potential for predicting readmission rates in atrial fibrillation patients. This study aimed to analyze the correlation between CHA2DS2-VA score assessment and the number of re-admissions within 180-day observation periode after the first admission of non-valvular atrial fibrillation patients. This study employed a retrospective cohort study design using data from the medical records of atrial fibrillation patients at Prof. Dr. R. D. Kandou Hospital from January to December 2024. The results showed that of the 143 study subjects, 30 patients (21%) experienced readmission and 113 patients (79%) did not experience readmission at 180 days after initial admission. Statistical analysis using Spearman’s rank test showed a statistically significant relationship between the CHA2DS2-VA score and the number of readmissions within 180 days (p=0.000). The relationship observed was a positive linear correlation with a moderate level (r=0.313). In conclusion, there is an increase of the 180-day readmission rate in patients with non-valvular atrial fibrillation as the CHA2DS2-VA score increases.
Keywords: CHA2DS2-VA score; patient readmission; atrial fibrillation
Abstrak: Tingkat readmisi pada pasien fibrilasi atrium masih menjadi beban tinggi bagi sistem kesehatan. Skor CHA2DS2-VA, sebagai alat ukur klinis yang inklusif dan praktis untuk memrediksi kejadian stroke juga memiliki potensi dalam memrediksi kejadian readmisi pada pasien fibrilasi atrium. Penelitian ini bertujuan untuk menganalisis hubungan antara penaksiran skor CHA2DS2-VA terhadap banyaknya readmisi dalam periode observasi 180 hari setelah admisi awal pada pasien fibrilasi atrium non-valvular. Jenis penelitian ialah studi kohort retrospektif menggunakan data rekam medis pasien fibrilasi atrium di RSUP Prof. Dr. R. D. Kandou periode Januari hingga Desember 2024. Hasil penelitian mendapatkan bahwa dari 143 subjek penelitian, terdapat 30 pasien (21%) yang mengalami readmisi, dan 113 pasien (79%) yang tidak mengalami readmisi pada pengamatan 180 hari sejak admisi awal. Uji Spearman’s rank menunjukkan terdapat hubungan bermakna antara skor CHA2DS2-VA dan jumlah kejadian readmisi dalam periode pengamatan 180 hari (p=0,000). Hubungan yang diamati berupa korelasi linear positif dengan tingkatan sedang (r=0,313). Simopulan penelitian ini ialah terdapat peningkatan kejadian readmisi dalam periode pengamatan 180 hari dan 90 hari pada pasien fibrilasi atrium non-valvular seiring dengan meningkatnya skor CHA2DS2-VA.
Kata kunci: skor CHA2DS2-VA; readmisi pasien; fibrilasi atrium
References
1. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur H J. 2024;45(36):3314–414. Doi: https://doi.org/10.1093/eurheartj/ehae176
2. Linz D, Gawalko M, Betz K, Hendriks JM, Lip GYH, Vinter N, et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health-Eur. 2024;37(1):100786(1-20). Doi: https://doi.org/10.1016/j.lanepe.2023.100786
3. Shantsila E, Choi EK, Lane DA, Joung B, Lip GYH. Atrial fibrillation: comorbidities, lifestyle, and patient factors. Lancet Reg Health-Eur. 2024;37(1):100784(1-26). Doi: https://doi.org/10.1016/j.lanepe.2023.100784
4. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;149(1):1–156. Doi: https://doi.org/10.1161/cir.0000000000001193
5. Chang SN, Wang CH, Waranugraha Y, Lin TT, Chen JJ, Huang PS, et al. Left atrial dimension and CHA2DS2-VASc score in predicting stroke in patients with rheumatic atrial fibrillation. JACC Advances. 2024;3(12):101343(1-10). Doi: https://doi.org/10.1016/j.jacadv.2024.101343
6. Zhang J, Lenarczyk R, Marin F, Malaczynska-Rajpold K, Kosiuk J, Doehner W, et al. The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. EP Europace. 2020;23(2):314–22. Doi: https://doi.org/10.1093/europace/euaa358
7. Rutland J, Ayoub K, Etaee F, Ogunbayo G, Darrat Y, Marji M, et al. CHA2DS2-VASc and readmission with new-onset atrial fibrillation, atrial flutter, or acute cerebrovascular accident. Int J Cardiol. 2020;323(1):72–6. Doi: https://doi.org/10.1016/j.ijcard.2020.08.027
8. Vitali F, Serenelli M, Airaksinen J, Pavasini R, Tomaszuk‐Kazberuk A, Mlodawska E, et al. CHA2DS2‐VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta‐analysis. Clin Cardiol. 2018;42(3):358–64. Doi: https://doi.org/10.1002/clc.23147
9. Maeda T, Nishi T, Funakoshi S, Tada K, Tsuji M, Satoh A, et al. Risks of bleeding and stroke based on CHA2DS2‐VASC scores in Japanese patients with atrial fibrillation: a large‐scale observational study using real‐world data. J Am Heart Assoc. 2020;9(5):014574(1-17). Doi: https://doi.org/10.1161/jaha.119.014574
10. Pramudyo M, Putra ICS, Pratama FB, Pranata R. Usefulness of the CHADS2 and CHA2DS2-VASC scores in predicting in-hospital mortality in acute coronary syndrome patients: a single-center retrospective cohort study. Indonesian J Cardiol. 2023;44(1):17–27. Available from: https://ijconline.id/index.php/ijc/article/view/1294
11. Kaneko H, Yano Y, Okada A, Itoh H, Suzuki Y, Yokota I, et al. Age‐dependent association between modifiable risk factors and incident cardiovascular disease. J Am Heart Assoc. 2023;12(2):027684(1-38). Doi: https://doi.org/10.1161/jaha.122.027684
12. Rajendran A, Minhas AS, Kazzi B, Varma B, Choi E, Thakkar A, et al. Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women. Atherosclerosis. 2023;384(1):117269(1-8). Doi: https://doi.org/10.1016/j.atherosclerosis.2023.117269
13. Bonnesen K, Heide-Jørgensen U, Sørensen HT, Schmidt M. Ability of the DANCAMI to predict the risk ischemic stroke and mortality in patients with atrial fibrillation/flutter. J Stroke Cerebrovasc Dis. 2023;32(8):107219(1-10). Doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107219
14. Tripathi B, Atti V, Kumar V, Naraparaju V, Sharma P, Arora S, et al. Outcomes and resource utilization associated with readmissions after atrial fibrillation hospitalizations. J Am Heart Assoc. 2019;8(19):013026(1-95). Doi: https://doi.org/10.1161/jaha.119.013026
15. Lahewala S, Arora S, Patel P, Kumar V, Patel N, Tripathi B, et al. Atrial fibrillation: Utility of CHADS 2 and CHA 2 DS 2 -VASc scores as predictors of readmission, mortality and resource utilization. International J Cardiol. 2017;245(1):162–7. Doi: https://doi.org/10.1016/j.ijcard.2017.06.090
16. Harb SC, Wang TKM, Nemer D, Wu Y, Cho L, Menon V, et al. CHA2DS2-VASc score stratifies mortality risk in patients with and without atrial fibrillation. Open Heart. 2021;8(2):001794(1-9). Doi: https://doi.org/10.1136/openhrt-2021-001794
17. Antoun I, Alkhayer A, Aljabal M, Mahfoud Y, Alkhayer A, Simon P, et al. Thirty-day unplanned readmissions following hospitalization for atrial fibrillation in a tertiary Syrian center: A real-world observational cohort study. Heart Rhythm O2. 2024;5(12):854–9. Doi: https://doi.org/10.1016/j.hroo.2024.05.010
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Zachary W. Kambey, Natalia I. Polii, Victor F. F. Joseph
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
